Halozyme Therapeutics Inc... (HALO)

NasdaqGS: HALO · 即時價格 · USD

98.66

-2.01 (-2.00%)

收盤時： Aug 14, 2026, 3:59 PM

98.25

-0.42%

盤後: 7:34 PM

-2.00% (1D)

買價	94.84
市值	11.2B
營收 (ttm)	1.66B
淨利（ttm）	413.6M
貝塔	0.85
EPS (ttm)	3.41
本益比（ttm）	29.54
正向 PE	9.49
P/B (ttm)	78.36
P/S (ttm)	6.73
Earnings Date	Nov 2, 2026

賣價	99
成交量	1,658,682
20 日平均成交量	2,007,175
打開	100.35
上一頁關閉	100.67
日間範圍	98.13 - 100.83
52 週範圍	61.23 - 104.78
分析師	Buy
目標價	105 (6.43%)
股利	n/a
Ex-股利日期	n/a

關於HALO

Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluid...

[閱讀更多]

工業 Biotechnology

部門 Healthcare

IPO 日期 Mar 16, 2004

員工 423

證券交易所 NasdaqGS

股票代號 HALO

網站 https://halozyme.com

完整的公司簡介

財務表現

Halozyme Therapeutics 在 2025 年的營收為 1.4B，較前一年的 1.02B 增加 37.55%。淨利為 316.89M，較前期減少 -28.64%。

財務報表

分析師預測

根據9 分析師評等，HALO股票的平均評等為「Buy」。 12個月股價預測為105，與最新價格相比為上漲空間的6.43%。

股票預測

獲利驚喜

Halozyme Therapeutics 已於 Aug 6, 2026 公布季度財報：

營收的 $481M 錯過估計 $0, 與 47.67% YoY 成長.

EPS 的 2.28 超出估計 0.46, 與 48.05% YoY 成長.

下次財報發布

Halozyme Therapeutics Inc. 定於發布財報 Nov 2, 2026, 在市場交易時間內。
分析師預估營收 ... 升級

新聞動態

剛才 · StockStory

The Top 5 Analyst Questions From Halozyme Therapeutics’s Q2 Earnings Call

Halozyme Therapeutics delivered a notably positive second quarter, as evidenced by the strong market reaction and management’s attribution of outperformance to surging royalty revenue and a wave of ne...

1 日前 · Insider Monkey

Incyte Corporation (INCY) has the Bigger Revenue Base, but Could Halozyme Therapeutics, Inc. (HALO) have the Better Economics?

On July 20, Halozyme Therapeutics, Inc. (NASDAQ:HALO) and Incyte Corporation (NASDAQ:INCY) announced a global collaboration and licensing deal to develop a subcutaneous formulation of Incyte’s INCA033...